You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A novel diagnostic test for Irinotecan and Topotecan sensitivity

    SBC: RG Biopharma            Topic: NCI

    DESCRIPTION (provided by applicant): The long term objective of this Phase 1 study is to produce an antibody-based diagnostic assay to detect tumor responsiveness to a widely used class of chemotherapeutic agents derived from camptothecin that includes Irinotecan and Topotecan. The assay will be based on a novel biomarker associated with cellular sensitivity to camptothecin and will have clinical ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  2. In-situ Gelling Protein Polymer Intravascular Embolic Agent for Hepatic Carcinoma

    SBC: THERATARGET, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): This Phase I proposal addresses the significant need for improved treatment options for patients with liver cancer, the fifth highest incidence of cance in the world. Because of the lack of symptoms, hepatocellular carcinoma (HCC) is detected at advanced stages in 84% of cases, for which the 1-year survival rate is 22% and at 5 years it is 5%. The only curativ ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  3. Integrin Targeted Therapy for the Treatment of Ovarian Cancer

    SBC: APPLIED INTEGRIN SCIENCES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Although prevention and early detection are the ultimate goals, the fact remains that 21,990 women in 2011 will be diagnosed with ovarian cancer in the U.S. Of these women 75% will be confronted with a high stage tumorand a five-year survival rate of 28%, which cannot be ignored. For these patients, improved treatment strategies for residual disease following s ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Devices enabling improved light delivery for photodynamic therapy of oral cancer

    SBC: LUCIFICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Oral cancer is a devastating disease that impacts 640,000 people worldwide. Though treatment with photodynamic therapy can be effective with significantly less morbidity than alternative therapies, problems arising fromless than optimal light delivery to the oral cavity have hindered its widespread application. The goal of the proposed research is to provide a ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  5. A Small Molecule to Activate Cetuximab to Kill K-RAS Mutant Colorectal Tumors

    SBC: ARISAPH PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): In the United States colorectal cancer (CRC) is the third leading cause of cancer mortality. Surgery is the primary treatment for early stage CRC; but adjuvant therapy is usually needed in advanced disease. Approximately 55% of CRC patients have metastatic disease for which the prognosis is poor despite incremental improvements due to introduction of irinotecan ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  6. Evaluation of In Vitro Companion Diagnostic Monoclonal Antibodies for Use in a St

    SBC: INTICA BIOMEDICAL, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): This project is designed to allow independent experts in the development and/or application of in vitro breast cancer diagnostic tests, Drs. Badve (breast pathologist) and Sledge (breast oncologist), to evaluate INTICA's candidate anti-DEspR mAbs to develop the preliminary materials and methods for a commercially viable companion diagnostic test. DEspR, th ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Design of a real-time dosimetry prototype for use with external beam radiotherapy

    SBC: Best Medical International, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Radiation oncology patients receive highly complicated treatments such as intensity modulated radiation therapy (IMRT), volumetric modulated arc therapy, stereotactic radiosurgery and stereotactic body radiation therapy using clinical linear accelerators. Currently, the quality assurance (QA) of a radiation treatment is don a priori to measure cumulative doses ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  8. Search Algorithms for Drug Combinations: Extending Approved Cancer Therapies

    SBC: SALGOMED, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Search algorithms for drug combinations: Extending approved cancer therapies. Combination drug therapy is commonly used to enhance efficacy and overcome drug resistance in cancer, but at present the choice of drugs is based on empirical clinical experience alone. Testing multi-drug therapies in a systematic way is hampered by the large number of possible choice ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Robotic Ultrasound Image Guidance System for Radiation Therapy

    SBC: SoniTrack Systems, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): External Beam Radiation Therapy (EBRT) is used in the disease management of more than half of all cancer patients worldwide. In order to advance the field of EBRT and improve treatment outcomes, highly conformal, potentablative doses must be delivered to maximize local tumor control and minimize toxicity to surrounding healthy tissue. Random and quasi-periodica ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Microfluidic Processing of Leukocytes for Molecular Diagnostic Testing

    SBC: GPB Scientific, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Microfluidic Processing of Leukocytes for Diagnostics Testing Summary/Abstract: New tests to quantify the numbers and functional states of key leukocyte types from blood samples offer enhanced determination and personalization of clinical diagnosis, prognosis, and treatment response. For example, labeling of gt30 cell surface and intracellular target molecules ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government